Natco Pharma Limited — Investor Meet, 14-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

NATCO Pharma posted strong Q1 FY27 results with total revenue at ₹794.4 Cr. International formulations led with ₹477.1 Cr, while domestic formulations added ₹136.4 Cr. EBITDA stood at ₹245.7 Cr, with margins at 30.9%, up from 25.1% QoQ. PAT was ₹206.5 Cr, with EPS at ₹11.53. Key operational wins include US FDA approval for Eribulin Mesylate Injection. The company continues to build its pipeline with several Para IV products and strategic investments in cutting-edge cell/gene therapy, showcasing a clear growth trajectory.